Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that ...

Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug ...

Ailux has announced a strategic collaboration with Eli Lilly and Company to accelerate the discovery and development of bispecific antibodies.

Swiss pharma giant Novartis has been on a deal spree ahead of several major patent expiries. In late October it agreed a $12 ...

DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Last year, China-based Jiangsu Hengrui Pharmaceuticals overtook the U.K.’s AstraZeneca as the top clinical trial sponsor in ...

LUND, SE / ACCESS Newswire / November 5, 2025 / Alligator Bioscience , a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication ...

Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

ASCO discussant Krina Patel, MD, of the University of Texas MD Anderson Cancer Center in Houston, noted, "Ciltacabtagene ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on ...

IBI3034 has the potential to become a best-in-class molecule with its advantages in depth of response, longer dosing interval and better convenience. The IND-enabling study of IBI3034 is ongoing for a ...